NDA/BLA filedconf 0.85

CLN-049 — NDA/BLA filed

$CGEM · Cullinan Therapeutics, Inc. · Relapsed/Refractory Acute Myeloid Leukemia (AML)

Event date

Date TBD

Sponsor runway

23 mo

$351.9M liquid

Evidence

“In December 2025, CLN-049 received Fast Track designation for the treatment of relapsed/refractory acute myeloid leukemia ("AML") from the United States Food and Drug Administration”

Source: 8-K filed 2026-01-08View on EDGAR ↗0001193125-26-006998

Comparable historical nda/bla fileds· last 5 years · same event type

Ticker	Drug	Date	Outcome
$AXSM	—	2025-12-31	unknown
$RCKT	kresladi	2025-10-14	unknown
$ALDX	reproxalap	2025-07-17	unknown
$ETON	et-600	2025-07-08	unknown
$BCRX	orladeyo (berotralstat)	2025-05-14	unknown
$CORT	relacorilant	2025-03-03	unknown
$ALDX	reproxalap	2024-11-01	unknown
$AXSM	axs-07	2024-09-04	unknown
$RCKT	kresladi	2023-10-02	unknown
$GERN	imetelstat	2023-08-21	unknown

Recent insider activity· ±90 days

1 insider · 0 buys · 2 sells

Exercise10b5-1

2026-05-05

Michaelson Jennifer

Chief Scientific Officer

4,000 @ $4.30$17K

Sell10b5-1

2026-05-05

Michaelson Jennifer

Chief Scientific Officer

7,800 @ $14.60$114K

Sell10b5-1

2026-05-05

Michaelson Jennifer

Chief Scientific Officer

200 @ $15.58$3K

Date	Insider	Action	Shares	Price	Value
2026-05-05	Michaelson JenniferChief Scientific Officer	Exercise10b5-1	4,000	$4.30	$17K
2026-05-05	Michaelson JenniferChief Scientific Officer	Sell10b5-1	7,800	$14.60	$114K
2026-05-05	Michaelson JenniferChief Scientific Officer	Sell10b5-1	200	$15.58	$3K

← All catalysts for $CGEM